Real-world Evaluation of Glycemic Control Among Patients with Type 2 Diabetes Mellitus Treated with Canagliflozin versus Dipeptidyl Peptidase-4 Inhibitors.

CONCLUSIONS: In this real-world study of patients with T2DM, CANA use was associated with greater HbA1c reduction and higher percentages of patients attaining HbA1c goals than those treated with DPP-4 inhibitors. PMID: 26938635 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/26938635?dopt=Abstract

Source: Current Medical Research and Opinion - March 6, 2016 Category: Research Tags: Curr Med Res Opin Source Type: research